In Tuesday’s Wall Street session, Vaxcyte Inc (NASDAQ:PCVX) shares traded at $32.23, down -14.65% from the previous session.
PCVX stock price is now -58.72% away from the 50-day moving average and -63.73% away from the 200-day moving average. The market capitalization of the company currently stands at $4.15B.
With the price target of $135, Goldman recently initiated with Buy rating for Vaxcyte Inc (NASDAQ: PCVX). On December 07, 2023, Mizuho recently initiated its ‘Buy’ rating on the stock quoting a target price of $69, while ‘TD Cowen’ rates the stock as ‘Outperform’
In other news, Eydelman Mikhail, SVP, GEN COUNSEL & CORP SEC sold 5,000 shares of the company’s stock on Mar 05 ’25. The stock was sold for $353,699 at an average price of $70.74. Upon completion of the transaction, the SVP, GEN COUNSEL & CORP SEC now directly owns 41,620 shares in the company, valued at $1.34 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 05 ’25, Officer Eydelman Mikhail bought 5,000 shares of the business’s stock. A total of $344,350 was incurred on buying the stock at an average price of $68.87. A total of 2.86% of the company’s stock is owned by insiders.
During the past 12 months, Vaxcyte Inc has had a low of $30.12 and a high of $121.06. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 12.75, and a quick ratio of 12.75. The fifty day moving average price for PCVX is $78.0819 and a two-hundred day moving average price translates $88.85358 for the stock.
The latest earnings results from Vaxcyte Inc (NASDAQ: PCVX) was released for 2024-12-31.
